Q4 EPS Forecast for Sangamo Therapeutics Lowered by Analyst

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Stock analysts at HC Wainwright dropped their Q4 2025 earnings estimates for shares of Sangamo Therapeutics in a research report issued on Monday, April 7th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their previous forecast of $0.01. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' FY2028 earnings at $0.15 EPS and FY2029 earnings at $0.38 EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million.

Several other research analysts also recently commented on SGMO. Truist Financial decreased their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. StockNews.com cut shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 24th. Jefferies Financial Group dropped their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, December 31st. Wells Fargo & Company decreased their price objective on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research report on Tuesday, December 31st. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Sangamo Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $5.17.

Sangamo Therapeutics Trading Up 3.9 %

Sangamo Therapeutics stock traded up $0.03 during trading on Wednesday, reaching $0.75. The company had a trading volume of 4,285,435 shares, compared to its average volume of 8,377,939. The firm has a market capitalization of $167.75 million, a price-to-earnings ratio of -1.00 and a beta of 1.57. The firm's 50-day simple moving average is $0.92 and its 200 day simple moving average is $1.39. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SGMO. Point72 Asset Management L.P. purchased a new position in shares of Sangamo Therapeutics in the 4th quarter worth $2,316,000. Geode Capital Management LLC lifted its holdings in shares of Sangamo Therapeutics by 3.4% in the 4th quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock worth $2,257,000 after acquiring an additional 73,540 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Sangamo Therapeutics during the 4th quarter worth about $1,744,000. Charles Schwab Investment Management Inc. grew its holdings in Sangamo Therapeutics by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company's stock valued at $1,162,000 after purchasing an additional 35,926 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in Sangamo Therapeutics by 222.1% in the fourth quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company's stock worth $1,033,000 after purchasing an additional 698,296 shares during the last quarter. Institutional investors own 56.93% of the company's stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.